Mid-Atlantic Section of the American Urological Association
Home | About Us | Contact Us   
  Home
  Members
    Members Only Area
    Member Directory
    Join the MA-AUA
  Annual Meeting
  Board of Directors
  Committees
  Careers
  Newsletters
  Visit the AUA
  Advocacy Efforts
  MAAUA Research
  Scholarship
Didusch Museum
About the Mid-Atlantic Section of the American Urological Association (MAAUA)

 
  Members Only
  Username
 
  Password
 
   Forgot Password?

 

2008 Annual Meeting Abstracts


Cryoablation Of Renal Fossa Recurrence Following Radical Nephrectomy
Kristina D. Suson, Michael Phelan
University of Maryland Medical Center, Baltimore, MD

Introduction - Renal fossa recurrence of renal cell carcinoma (RCC) following radical nephrectomy historically requires open surgical resection. The failure rate is high (50%), and the procedure is associated with a high morbidity. Cryoablation of a solitary, local recurrence may provide a minimally invasive alternative to open resection. We describe our experience in treating two patients experiencing fossa recurrence with percutaneous cryoablation.
Methods - We retrospectively reviewed medical records of two patients with renal fossa recurrence of RCC treated with percutaneous cryoablation.
Results - Two patients developed remote local recurrence following radical nephrectomy and underwent percutaneous cryoablation with 17-gauge needles and two freeze-thaw cycles. A 69 y/o male with a history of bilateral nephrectomy for clear cell carcinoma developed a 3.2 cm recurrence 6 years after surgery. He received percutaneous cryoablation with four needles. After nine months, the mass showed continued enhancement, and he underwent a second treatment for biopsy-proven clear cell carcinoma. Surveillance imaging for the past 18 months is free of residual disease. A 52 y/o male received percutaneous cryoablation with three needles for a 2.3 cm mass that recurred 17 months after radical nephrectomy for clear cell carcinoma. One year after cryoablation, he underwent surgical extirpation. He is currently receiving Sutent for metastatic disease. Both patients tolerated percutaneous cryoablation well and were discharged home within 24 hours.
Conclusions - Percutaneous cryoablation provides a minimally invasive intervention with low morbidity. However, the patient requires close follow-up and may require re-treatment.


 

 

Copyright © 2012 Mid-Atlantic Section of the American Urological Association. All Rights Reserved.
Read Privacy Policy.